Naslov
Palliative role of chemotherapy in patients with nonresectable cacner of the billiary system or advanced gallblader cancer
(Palliative role of chemotherapy in patients with nonresectable cancer of the billiary system or advanced gallblader cancer)

Autori
Dobrila-Dintinjana, Renata ; Štimac, Davor ; Ružić, Alen ; Dintinjana, Renata

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Supportive Care in Cancer / H.J.Senn - Philadelphia (PA) : Springer, 2003, 414-415

Skup
15th MASCC International Symposium

Mjesto i datum
Berlin, Njemačka, 18.06.2003. - 21.06.2003

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
palliative role; chemotherapy; nonresectable cancer; billiary system; advanced gallblader cancer
(palliative role; chemotherapy; nonresectable cacner; billiary system; advanced gallblader cancer)

Sažetak
Introduction : Adenocarcinomas of the bile ducts (BSCa) and gallblader (GBCa) are highly malignant neoplasms with a very poor prognosis.Chemotherapy (cht) often plays only a palliative role and responses are transient without prolonged survival. Aim of the study : to evaluate effectivenes of gemcitabine (G) and cisplatin (C) combination protocol in achieveing Clinical Benefit Response (CBR) for patients (pts) with nonresectable BSCa and with advanced GBCa.Results : during four years period we curred 30 pts with BSCa and GBCa with mean age of 50+5, 4 years.There was 18 females with mean age of 48, 2+4, 6 years and 12 men with mean age 52, 6+4, 6 years.20 pts (66, 7%) had locally advanced disease and 10 pts (33, 3%)metastatic disease.Pts achieved G 1000 mg/m2 intravenous once per week for seven times.CP 100 mg/m2 iv was administered at day 1, 15, 29 and 43.Number of applicated cycles was 1-10 (median 4 cycles).Global response rate achieved 18 pts (60%), also as partial response rate (18 pts-60%).All pts (100%) achieved CBR.Pain measured at VAS scale before cht was 4, 8 ; and after first cycle 1, 6.Karnofsky Performance Status (KPS) before chemotherapy was 60% and after 1st cht cycle 80%.Median Duration Clinical Benefit was 22 weeks. Conclusion : This results indicate that the treatment of GBCa and BSCa with Gemcitabine and Ciplatinum is effective, well tolerated and leads to Clinical Benefit.We can also confirm that the role of cht is not only prolonging survival time but allso palliation and achieving better Qualitiy of Life.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita

POVEZANOST RADA